Uncategorized
Humanized monoclonal antibody shows promise in treating geographic atrophy
HAMBURG — Lampalizumab, a humanized, monoclonal antibody directed against complement factor D, showed high safety profile and efficacy in inhibiting geographic atrophy in a study presented at the Euretina meeting. “This study represents a breakthrough, because for the first time we have a potential treatment option for geographic atrophy,” Frank G. Holz, MD, said.